AZD1775 in Women With Recurrent or Persistent Uterine Serous Carcinoma or Uterine Carcinosarcoma

Uterine Cancer Clinical Trial

Official title: A Phase 2 Study of the Wee1 Inhibitor AZD1775 in Women With Recurrent or Persistent Uterine Serous Carcinoma or Uterine Carcinosarcoma

Status Active, not recruiting

Clinical Trial Summary

This research study is studying an investigational drug as a possible treatment for uterine cancer. The drug involved in this study is: -AZD1775

Clinical Trial Description

This research study is a Phase II clinical trial. Phase II clinical trials test the safety and effectiveness of an investigational drug to learn whether the drug works in treating a specific disease. "Investigational" means that the drug is being studied. The FDA (the U.S. Food and Drug Administration) has not approved AZD1775 as a treatment for any disease. The "investigational drug" AZD1775 is being given alone to patients with this type of cancer. AZD1775 is also being studied in lung cancer, ovarian cancer, and other solid tumors throughout the world. AZD1775 blocks the activity of Wee1, a protein that helps to regulate how cells divide and grow. Certain cancer cells may be more vulnerable to having this process blocked. This study is being done to assess the safety and effectiveness of AZD1775 to learn if AZD1775 works in treating this type of cancer. ;

Related Conditions & MeSH terms

• Carcinosarcoma
• Mixed Tumor, Mullerian
• Uterine Cancer
• Uterine Neoplasms

• NCT number: NCT03668340
• Study type: Interventional
• Source: Dana-Farber Cancer Institute
• Status: Active, not recruiting
• Phase: Phase 2
• Start date: October 22, 2018
• Completion date: December 31, 2025